semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Healthy Body mass index (BMI) between 25.0 and 40.0 kilogram per square meter ( kg/m^2), inclusive, and a body weight of not less than 80 kg Blood pressure (BP) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic If a woman, must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening If a woman, must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study (from screening through Day 56) or until 30 days after the last dose of study drug for participants that withdraw early from the study QRS interval of less than or equal to (<=) 110 milliseconds (ms) An average of triplicate 12-lead safety electrocardiogram (ECG) recording, completed within 4 minutes total, consistent with normal cardiac conduction and function at screening, including 1. Normal sinus rhythm (heart rate between 45 and 100 beats per minute [inclusive]) 2. QT interval corrected for heart rate according to Fridericia's formula (QTcF) interval between 350 to 450 ms (inclusive) 3. PR interval <= 200 ms 4. ECG morphology consistent with healthy cardiac conduction and function  Taken any disallowed therapies as defined in a protocol before the planned first dose of study drug Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or at admission to the study Clinically significant abnormal physical examination, vital signs, or 12 lead electrocardiogram at screening or at admission to the study site Known allergies, hypersensitivity, or intolerance to JNJ-64565111, moxifloxacin, or its excipients Hepatitis B or C infection History of additional risk factors for torsade de pointes or the presence of a family history of Short QT Syndrome, Long QT Syndrome, sudden unexplained death at a young age (<= 40 years), or sudden infant death syndrome in a first-degree relative (that is biological parent, sibling, or child)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Ankle Fractures Patients who were between the ages of 18 to 65 and were going to be operated due to lateral and/or medial malleolus fracture
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 29.0-35.0,  Labor Long Nulliparity Premature Rupture of Membrane Pregnancy, Prolonged Pregnancy Women who Are 18 years-of-age or older With gestation between 37-41+3 weeks Have signed an informed consent form  The following will apply Women who do not have sufficient understanding of the Spanish language or those with whom communication will be difficult Women with a multiple gestation Gestation with high maternal or neonatal risk Maternal pathology (metabolic diseases, preeclampsia, eclampsia, etc.) Fetal pathology Precipitated delivery; fetal death. for leaving the study Severe maternal complications during the immediate or intermediate postpartum periods that require admittance to the Intensive care Unit Neonatal complications that require admittance to the Neonatology Service for more than 48 hours
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Rheumatoid Arthritis patients with rheumatoid arthritis diagnosed based on american collegue of rheumatology 2010 with no history of vit D therapy  patients with rheumatoid arthritis on vit D supplements patient refusal patient not fullfill american collegue of rheumatology 2010 citeria for diagnosis pf rheumatoid arthritis
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-45.0,  Hepatitis B Infection Considered healthy as per medical judgment of the investigator 2. Age: 20 to 45 years 3. Sex: Male, Female and Transgender 4. For married women, a negative urine pregnancy test (Rapid Diagnostic Test) during screening and prior to first, second and third dose of vaccination.Moreover, medical history will be taken thoroughly by study physician from the woman of childbearing age to completely the probability of pregnancy.The women who are married and living with a partner must agree to use a reliable contraceptive method to prevent pregnancy until final follow-up following vaccination. However abstinence is also acceptable  Prior history of hepatitis B infection 2. Vaccination with any hepatitis B vaccine 3. Recent febrile illness (within 2 weeks) 4. Known or suspected hypersensitivity to any component of Hepatitis B vaccine (e.g., aluminium, yeast). 5. History of received hepatitis B immune globulin (HBIG), serum immune globulin, or any other blood-derived product. 6. Known or suspected impairment of immunologic function or recent use of immunomodulatory medications (e.g., systemic corticosteroids) more than 14 days with in last 6 months. Does not topical and inhaled steroids. 7. Receipt of investigational drugs or other investigational vaccines within 3 months prior to first injection with the study vaccine. 8. Pregnant women, nursing mothers, and women planning to become pregnant within the study period. 9. HBsAg reactive, anti-HBs antibody (≥10mlU/ml), anti-HBc (total) reactive, and abnormal liver function test [serum alanine aminotransferase (ALT) level], serum creatinine and CBC (As mentioned in Appendix IV)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 9.0-999.0,  Sickle Cell Anemia in Children Vitamin A Deficiency in Children Sickle cell disease, SS genotype (subjects with sickle cell disease only) Usual state of good health (no hospitalizations, emergency room visits, or unscheduled acute illness clinic visits for two weeks prior to screening) Commitment to a 119-day study (subjects with sickle cell disease only), or a 4-day study (healthy volunteers only)  Hydroxyurea initiated within the previous 6 weeks (subjects with sickle cell disease only) History of stroke (subjects with sickle cell disease only) Other chronic conditions that may affect growth, dietary intake or nutritional status Retinoic acid (topical or oral), weight loss medication and/or lipid lowering medications Subjects with a BMI greater than 98th percentile for age and sex Pregnant or lactating females (subjects who become pregnant during the course of the study will not continue participation) Liver function tests >4 x upper limit of reference range Participation in another study with impact on vitamin A status (subjects with sickle cell disease only) Use of multi-vitamin or commercial nutritional supplements containing vitamin A (those who are willing to discontinue these supplements, with the approval of the medical care team, will be eligible for the study after a 1 month washout period. Subjects taking nutritional products without vitamin A will be eligible) Inability to swallow pills (subjects with sickle cell disease only)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Pain Between age 18-40 2. Normal BMI (18.5-25.0) 3. HR 60-100 bmp 4. BP less than or equal to 140/90  Age <18 or >40 years 2. Cardiac, respiratory, neurological or musculoskeletal disease 3. Acute pain 4. Chronic pain condition 5. Diabetes 6. BMI ≥ 25.1 or ≤ 18.4 7. Regular participation in high intensity athletic/sporting activities 8. Sedentary 9. Anxiety or depression disorders 10. Tape allergy 11. Currently pregnant
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 16.0-48.0,  Polycystic Ovary Syndrome Vitamin D Deficiency Vitamin D deficient premenopausal women  Pregnant women Women during their postpartum period Breastfeeding women Women taking any kind of exogenous hormones Women receiving any form of oral vitamin D replacement
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitamin D Deficiency Hemodialysis Patient Age 18 or over signed informed consent form ESRD with regular dialysis treatment for at least 3 months levels of 25VD < 30 ng / ml levels of iPTH >300 ng/ml stable doses of calcitrol or paricalcitol over the last 30 days  Congestive heart failure class III or IV unstable angina or myocardial infarction or stroke during the previous 3 months active malignant neoplasm use of any trial medication life expectancy lower than 6 months corrected calcemia ≥ 10.5 in the 2 months prior to recruitment intake of cholecalciferol or ergocalciferol in the 2 months prior to recruitment prospective move to another city or transfer to PD in the following 6 months
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.462-0.615,  Infant, Premature, Diseases gestational age ≤32 weeks at birth hospitalization in the department no later than at the age of 7 days (for infants born outside the center) No birth defects or diseases permanently affecting the ability to accept enteral feeding Anticipated possibility of continuous monitoring of the course of treatment in hospital until discharge Consent of Parents / legal guardians for the participation in the study  gestational age> 32 weeks at birth the beginning of hospitalization in the department later than the age of 7 days (for infants born outside the center) presence of congenital defects or diseases permanently affecting the ability to accept enteral feeding (e.g.oesophageal atresia, anal atresia, congenital umbilical hernia, gastroschisis, syndromes genetically determined) significant interruption (> 1 week) of the hospitalization in the center lack of consent of the Parents / legal guardians to participation in the study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 25.0-55.0,  Vitamin D Deficiency jordanian people aged 25-55 medical diagnosis of vitamin D deficiency ( VD <25 ng/ ml)  Blood disorders including thalassemia sickle cell disease
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Phosphorus and Calcium Disorders Parathyroid Diseases Hyperparathyroidism Hypoparathyroidism patients with diagnosis of primary hyperparathyroidism patients with diagnosis of hypoparathyroidism subjects with normal Calcium-Phosphorus metabolism  for both cases and controls will be age younger than 18 or older than 90 years severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min) hyperparathyroidism secondary to Vitamin D deficiency active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc) any type of cancer malnutrition severe obesity (BMI > 40 kg/m2) a history of gastrointestinal malabsorption sarcoidosis
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 6.0-70.0,  X-linked Hypophosphatemia Hypophosphatemic Rickets Hypophosphatemic Rickets, X-Linked Dominant Clinical diagnosis of XLH with family history excluding male-to-male transmission, or positive genotype for PHEX mutation Serum PTH levels less than 1.5x the upper limit of normal Serum calcium levels less than 10.0 mg/dl eGFR >= 60 mL/min/1.73m2 OH) vitamin D level >= 20 ng/dL  Known allergy to calcitriol Pregnancy or breast feeding Use of skeletally active agents such as bisphosphonates, teriparatide, SERMS, hormone replacement therapy and progesterone-only contraceptive agents (combination oral contraceptive use in premenopausal women is not an criterion) Unwilling or unable to stop therapy with calcitriol and phosphate therapy for two weeks prior to study Therapy with cinacalcet within the past two weeks Current use of growth hormone therapy Use of diuretics or medications that alter renal handling of mineral ions Use of glucocorticoids for more than 14 days in the past 12 months with the exception of inhaled agents History of malignancy except basal and squamous cell carcinoma of the skin Significant history of psychiatric disease per DSM-5
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 45.0-65.0,  Cardiovascular Risk Factor Menopause Related Conditions Neuromuscular Function Aerobic Capacity Inflammation provide written and dated informed consent to participate in the study; (2) be willing and able to comply with the protocol be willing and able to comply with the protocol be a female between the ages of 45 and 65, inclusive be postmenopausal for ≥ 1 year be in good health and free from chronic cardiovascular, pulmonary, or musculoskeletal disease as determined by a health history questionnaire have a BMI between 18.5 and 40.0, inclusive; and answer no to all questions on the PAR-Q for people aged 15 to 69, which are as follows: 1. Has your doctor ever said that you have a heart condition and that you should only do physical activity recommended by a doctor? 2. Do you feel pain in your chest when you do physical activity? 3. In the past month, have you had chest pain when you were not doing physical activity? 4. Do you lose your balance because of dizziness or do you ever lose consciousness? 5. Do you have a bone or joint problem that could be made worse by a change in physical activity? 6. Is your doctor currently prescribing drugs for your blood pressure or heart condition? Do you know of any other reason why you should not do physical activity?  are currently prescribed and/or taking lipid-lowering medications are participating in another clinical trial within thirty days prior to enrollment
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse) Mental Health Wellness 1 War-Related Trauma Participants who will be recruited in the study are adult and adolescent (13-19 years) refugees, Syrian and non-Syrians, who are currently residing in Amman, Jordan who will be participating in the MRTP at CRP  Jordanian refugees residing in Amman, Jordan
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Osteoarthritis, Knee Age 18-70 years Kellgren-Lawrence grade 2 in the tibiofemoral joint The patient must be expected to be able to attend follow up examinations The patient must be able to speak and understand Danish The patient must be able to give informed consent 5.3  Smoking (the patient must consent to being non-smoking 6 weeks pre and post the procedure) Varus or valgus malalignment of the knee > 5 degrees Laxity of the MCL or LCL of 10 degrees or more compared to the opposite knee Knee instability and anterior-posterior laxity of 3mm or above Preceding open surgery to the knee or fracture in the proximal tibia or distal femur Extension deficit of the knee Kellgren-Lawrence grade 4 in any of the three compartments BMI > 40 Terminal illness or severe medical illness: ASA score higher than or equal to 3
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Sacroiliac Joint Dysfunction Male and female patients aged 18-60 2. Based on the diagnostic proposed by the International Association for the Study of Pain (IASP): i.Pain in the SIE region (hip/groin or lower extremity) ii.The pain felt in SIS, revitalized by specific provocation tests 3. Patients with sacroiliac joint dysfunction and validity-validity-tested provocation tests, at least 3 of 6 tests are positive 1.Distraction 2.Compression 3.Gaenslen 4.POSH Test ( Thigh Thrust) 5.Sacral Push 6.FABER 4. Patients excluded from the presence of sacroiliitis by previous examinations and examinations 5. The signing of the informed consent form  Severe cognitive dysfunction 2. The presence of a neurological deficit in the lower extremity 3. Presence of known central nervous system or peripheral nervous system disease 4. Presence of known rheumatic disease (rheumatoid arthritis, ankylosing spondylitis, etc.) 5. Have undergone major surgery for lower back and waist 6. Pregnancy 7. Spondylolisthesis 8. Built-in osteoporosis 9. The presence of malignancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Low Back Pain Sacroiliac Disorder dysfunction or sacroiliac joint hypomobility (SI) having stopped taking anti-inflammatory medicines or analgesics three days before the study began  destructive injuries of the spine and pelvis fractures lumbar surgery sacroiliac instability spondylolisthesis pregnancy in progress cauda equina syndrome abdominal aneurysm infection inflammatory arthritis